LOGIN  |  REGISTER
Viking Therapeutics

Travere Therapeutics to Present at Upcoming Investor Conferences

February 26, 2024 | Last Trade: US$18.25 0.01 -0.05

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:

Cowen 44th Annual Health Care Conference
Monday, March 4, 2024, at 9:10 a.m. ET

Leerink Partners Global Biopharma Conference
Monday, March 11, 2024, at 1:20 p.m. ET

Barclays 26th Annual Global Healthcare Conference
Tuesday, March 12, 2024, at 2:05 p.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contact Info

Media:
888-969-7879
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
888-969-7879
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB